Goldman Sachs Group Inc. Has $682,000 Stock Position in Ventyx Biosciences, Inc. $VTYX

Key Points

• Goldman Sachs Group Inc. reduced its holdings in Ventyx Biosciences by 60.7%, owning approximately 593,248 shares valued at $682,000 as of the end of the first quarter.
• Several institutional investors made significant changes to their stakes, including AQR Capital Management LLC, which increased its stake by 925.6% to own 880,222 shares valued at $1,012,000.
• Ventyx Biosciences' stock is currently rated as a "Moderate Buy" with an average price target of $7.50, despite shares being down 1.8% at $2.75.

Goldman Sachs Group Inc. lowered its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 60.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 593,248 shares of the company's stock after selling 917,509 shares during the period. Goldman Sachs Group Inc. owned approximately 0.83% of Ventyx Biosciences worth $682,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Acadian Asset Management LLC grew its stake in Ventyx Biosciences by 443.8% in the first quarter. Acadian Asset Management LLC now owns 537,054 shares of the company's stock valued at $614,000 after acquiring an additional 438,286 shares during the period. Jane Street Group LLC acquired a new stake in Ventyx Biosciences in the first quarter valued at approximately $56,000. AQR Capital Management LLC grew its stake in Ventyx Biosciences by 925.6% in the first quarter. AQR Capital Management LLC now owns 880,222 shares of the company's stock valued at $1,012,000 after acquiring an additional 794,401 shares during the period. ADAR1 Capital Management LLC grew its stake in Ventyx Biosciences by 126.1% in the first quarter. ADAR1 Capital Management LLC now owns 281,600 shares of the company's stock valued at $324,000 after acquiring an additional 157,070 shares during the period. Finally, Redmile Group LLC grew its stake in Ventyx Biosciences by 1,164.1% in the first quarter. Redmile Group LLC now owns 1,569,793 shares of the company's stock valued at $1,805,000 after acquiring an additional 1,445,615 shares during the period. Institutional investors and hedge funds own 97.88% of the company's stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Ventyx Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $7.50.

Ventyx Biosciences Stock Down 1.8%

Shares of NASDAQ:VTYX opened at $2.75 on Thursday. The stock has a market cap of $196.10 million, a price-to-earnings ratio of -1.64 and a beta of 0.95. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $3.39. The business's 50 day moving average is $2.66 and its 200 day moving average is $2.01.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.07. As a group, equities research analysts expect that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Want to see what other hedge funds are holding VTYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.